About: A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice
Creator	Xia, Xianzhu Yang, Songtao Zhang, Ying Wang, Jianzhong Bi, Yuhai Chi, Hang Feng, Na Gao, Yuwei Wang, Hualei Wang, Tiecheng Zhao, Yongkun Zhang, Shengnan Huang, Pei Jin, Hongli Li, Entao Li, Guohua Liu, Chuanyu Mo, Ruo Sun, Weiyang Wang, Zhenshan Yan, Feihu
topic	covid:89fc23ed55ad474b4b4056c0a3dadd315573f57e#this
source	Medline; PMC; WHO
abstract	Middle East respiratory syndrome coronavirus (MERS-CoV), a new coronavirus that has been causing severe and fatal acute respiratory illnesses in humans since its outbreak in 2012, has raised public fear worldwide. The development of prophylactics and therapeutics is urgently needed to prevent and control MERS-CoV infections. In this study, a bacterium (Lactococcus lactis)-like particle (BLP) vaccine displaying the MERS-CoV receptor-binding domain (RBD) was developed, and gram-positive enhancer matrix (GEM) particles were used as substrates to externally bind to the MERS-CoV RBD through a protein anchor (PA). The designs included different numbers of lysin motif (LysM) repeats in the PAs linked by linkers (RBD-linker-PA2 (RLP(2)), RBD-linker-PA3 (RLP(3)) and RBD-PA3 (RP(3))), and three LysM repeats and a linker in the fusion proteins increased the binding activity to the RBD. The specific immune responses were tested by intranasally immunizing mice with RLP(3)-GEM with or without the adjuvant GEL01. The results showed that GEL01-adjuvanted RLP(3)-GEM increased the systemic humoral, cellular and local mucosal immune responses in the mouse model, especially in the intestinal tract. The above results indicate that the MERS-CoV BLP product has the potential to be developed into a promising mucosal candidate vaccine to protect against MERS-CoV infections.
has issue date	2019-08-29(xsd:dateTime)
bibo:doi	10.3390/v11090799
bibo:pmid	31470645
has license	cc-by
sha1sum (hex)	89fc23ed55ad474b4b4056c0a3dadd315573f57e
schema:url	https://doi.org/10.3390/v11090799
resource representing a document's title	A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice
has PubMed Central identifier	PMC6784119
has PubMed identifier	31470645
schema:publication	Viruses
resource representing a document's body	covid:89fc23ed55ad474b4b4056c0a3dadd315573f57e#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/89fc23ed55ad474b4b4056c0a3dadd315573f57e
is schema:about of	named entity 'vaccine' covid:arg/89fc23ed55ad474b4b4056c0a3dadd315573f57e named entity 'product' named entity 'therapeutics' named entity 'RLP' named entity 'candidate' named entity 'infections' named entity 'causing' named entity 'control' named entity 'RBD' named entity 'infections' named entity 'adjuvant' named entity 'mice' named entity 'RBD' named entity 'mucosal' named entity 'Middle East respiratory syndrome' named entity 'Mucosal' named entity 'Domain' named entity 'RBD' named entity 'MERS-CoV' named entity 'RBD' named entity 'vaccine' named entity 'Middle East respiratory syndrome coronavirus' named entity 'fusion proteins' named entity 'intestinal tract' named entity 'mouse model' named entity 'binding activity' named entity 'RBD' named entity 'RBD' named entity 'MERS-CoV' named entity 'gram-positive' named entity 'Mice' named entity 'MERS-CoV' named entity 'supernatants' named entity 'activated B cells' named entity 'adjuvants' named entity 'antigen' named entity 'RBD' named entity 'intranasally' named entity 'cellular immune responses' named entity 'Gly' named entity 'antigen' named entity 'immunization' named entity 'IgA' named entity 'immune response' named entity 'Th1' named entity 'intranasally' named entity 'IgG' named entity 'antigen' named entity 'Grand Island, NY' named entity 'IFN' named entity 'splenocyte' named entity 'IgG1' named entity 'supernatant' named entity 'proliferative index' named entity 'IgG2a' named entity 'functional domains' named entity 'acetone' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software